Patents by Inventor Bettina Rudolph
Bettina Rudolph has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8957020Abstract: This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing obesity, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the animal or human subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing obesity.Type: GrantFiled: September 26, 2011Date of Patent: February 17, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Arnd Steuernagel, Karsten Eulenberg, Guenter Broenner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jaekel, Christoph Meyer
-
Patent number: 8828934Abstract: This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing a pancreatic malfunction, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing a pancreatic malfunction.Type: GrantFiled: September 26, 2011Date of Patent: September 9, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Arnd Steuernagel, Karsten Eulenberg, Guenter Broenner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jaekel, Christoph Meyer
-
Publication number: 20120129817Abstract: The subject matter of this application is directed to combinations of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-2-ol with other active compounds for the treatment of diabetes mellitus type 2 and/or type 1.Type: ApplicationFiled: February 1, 2012Publication date: May 24, 2012Applicant: NYCOMED GMBHInventors: Thomas KLEIN, Anja BLASER, Bettina RUDOLPH, Ulrich KAUTZ, Jens SELIGE, Wolfgang KROMER
-
Publication number: 20120045451Abstract: This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing obesity, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the animal or human subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing obesity.Type: ApplicationFiled: September 26, 2011Publication date: February 23, 2012Applicant: DeveloGen Aktiengesellschaft fuer Entwicklungsbiologische ForschungInventors: Arnd Steuernagel, Karsten Eulenberg, Guenter Broenner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jakel, Christoph Meyer
-
Publication number: 20120045452Abstract: This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing a pancreatic malfunction, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing a pancreatic malfunction.Type: ApplicationFiled: September 26, 2011Publication date: February 23, 2012Applicant: DeveloGen Aktiengesellschaft fuer Entwicklungsbiologische ForschungInventors: Arnd Steuernagel, Karsten Eulenberg, Günter Brönner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jäkel, Christoph Meyer
-
Patent number: 8076098Abstract: The present invention discloses Mnk homologous proteins regulating the energy homeostasis, the metabolism of triglycerides, and/or is contributing to membrane stability and/or function of organelles, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases and disorders related to body-weight regulation and thermogenesis, for example, but not limited to, metabolic diseases such as obesity, as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, and sleep apnea, and disorders related to ROS defence, such as diabetes mellitus, neurodegenerative disorders, and cancer, e.g. cancers of the reproductive organs, and others.Type: GrantFiled: July 16, 2008Date of Patent: December 13, 2011Assignee: Boehringer Ingelheim International GmbHInventors: Arnd Steuernagel, Karsten Eulenberg, Guenter Broenner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jaekel, Christoph Meyer
-
Publication number: 20100179131Abstract: The invention relates to combinations of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridine-2-ol with other active compounds for the treatment of diabetes mellitus type 2 and/or type 1.Type: ApplicationFiled: September 4, 2007Publication date: July 15, 2010Applicant: NYCOMED GMBHInventors: Thomas Klein, Anja Blaser, Bettina Rudolph, Ulrich Kautz, Jens Selige, Wolfgang Kromer
-
Publication number: 20080226638Abstract: Provided herein are methods for the treatment of metabolism disorders by delivering a therapeutically effective amount of a modulator of a SOUP1 polypeptide. The invention also relates to a nucleic acid molecule encoding a polypeptide contributing to membrane stability and/or function of organelles.Type: ApplicationFiled: January 5, 2007Publication date: September 18, 2008Applicant: DEVELOGEN AG FUR ENTWICKLUNGSBIOLOGISCHE FORSCHUNGInventors: Arnd Steuernagel, Gunter Bronner, Cord Dohrmann, Thomas Ciossek, Roland Wehr, Bettina Rudolph, Dorothea Rudolph
-
Publication number: 20070110728Abstract: The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a DG119-1 product or a DG119-1 agonist and/or an antagonist To a DG 119-2 product.Type: ApplicationFiled: November 29, 2004Publication date: May 17, 2007Applicant: DEVELOGEN AKTIENGESELLSCHAFTInventors: Matthias Austen, Daria Onichtchouk, Thomas Siegmund, Kristin Aduroja, Bettina Rudolph, Friedrich Harder
-
Publication number: 20050176659Abstract: The present invention discloses Endophilin homologous proteins regulating the energy homeostasis and the metabolism of triglycerides, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases and disorders, for example, but not limited to, metabolic diseases such as obesity as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, cancers of the reproductive organs, and sleep apnea.Type: ApplicationFiled: November 8, 2002Publication date: August 11, 2005Inventors: Bettina Rudolph, Ursula Hoffmann, Karsten Eulenberg, Roland Wehr, Gunter Bronner, Arnd Steuernagel, Thomas Hader
-
Publication number: 20050080026Abstract: The present invention discloses Mnk homologous proteins regulating the energy homeostasis, the metabolism of triglycerides, and/or is contributing to membrane stability and/or function of organelles, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases and disorders related to body-weight regulation and thermogenesis, for example, but not limited to, metabolic diseases such as obesity, as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, and sleep apnea, and disorders related to ROS defence, such as diabetes mellitus, neurodegenerative disorders, and cancer, e.g. cancers of the reproductive organs, and others.Type: ApplicationFiled: October 29, 2002Publication date: April 14, 2005Inventors: Arnd Steuernagel, Karsten Eulenberg, Gunter Bronner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jakel, Christoph Meyer